205 related articles for article (PubMed ID: 8021731)
21. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
23. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
[TBL] [Abstract][Full Text] [Related]
24. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
Evans TR; Yellowlees A; Foster E; Earl H; Cameron DA; Hutcheon AW; Coleman RE; Perren T; Gallagher CJ; Quigley M; Crown J; Jones AL; Highley M; Leonard RC; Mansi JL
J Clin Oncol; 2005 May; 23(13):2988-95. PubMed ID: 15860854
[TBL] [Abstract][Full Text] [Related]
25. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
26. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Burke TW; Stringer CA; Morris M; Freedman RS; Gershenson DM; Kavanagh JJ; Edwards CL
Gynecol Oncol; 1991 Mar; 40(3):264-7. PubMed ID: 2013451
[TBL] [Abstract][Full Text] [Related]
27. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
[TBL] [Abstract][Full Text] [Related]
28. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.
Overmoyer B; Silverman P; Holder LW; Tripathy D; Henderson IC
Clin Breast Cancer; 2005 Jun; 6(2):150-7. PubMed ID: 16001993
[TBL] [Abstract][Full Text] [Related]
29. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.
Burke TW; Gershenson DM; Morris M; Stringer CA; Levenback C; Tortolero-Luna G; Baker VV
Gynecol Oncol; 1994 Oct; 55(1):47-50. PubMed ID: 7959265
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.
Loehrer PJ; Kim K; Aisner SC; Livingston R; Einhorn LH; Johnson D; Blum R
J Clin Oncol; 1994 Jun; 12(6):1164-8. PubMed ID: 8201378
[TBL] [Abstract][Full Text] [Related]
31. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
[TBL] [Abstract][Full Text] [Related]
33. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD
Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
35. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
36. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
37. Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide.
Campora E; Vidali A; Mammoliti S; Ragni N; Conte PF
Eur J Gynaecol Oncol; 1990; 11(3):181-3. PubMed ID: 2209636
[TBL] [Abstract][Full Text] [Related]
38. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
[TBL] [Abstract][Full Text] [Related]
39. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic cooperative oncology group study.
Bafaloukos D; Aravantinos G; Samonis G; Katsifis G; Bakoyiannis C; Skarlos D; Kosmidis P
Oncology; 1999 Apr; 56(3):198-201. PubMed ID: 10202274
[TBL] [Abstract][Full Text] [Related]
40. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Giaccone G; Dalesio O; McVie GJ; Kirkpatrick A; Postmus PE; Burghouts JT; Bakker W; Koolen MG; Vendrik CP; Roozendaal KJ
J Clin Oncol; 1993 Jul; 11(7):1230-40. PubMed ID: 8391065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]